2021
Signature of an exclusive licensing agreement with Université Laval regarding the use and development of proprietary and patented blood biomarkers for Parkinson’s disease.
2022
Signature as an industry and financial partner to an academic grant to Dr. Cicchetti from le ministère de l’Économie, de l’Innovation et de l’Énergie (MEI-Quebec Gouvernent).
2023
Completion of a drug development plan in collaboration with a group of experts and consultants regarding a novel formulation of Cysteamine called SYN-001, best suited to meet the clinical needs in Parkinson’s disease.
2024
Successful completion of a seed financing of $3.5M with seasoned private investors and 2 key institutions from the province of Quebec.
